{"entity":{"id":"fang-wenfeng","kind":"person","name":"Wenfeng Fang","aka":[],"tldr":"Wenfeng Fang is a lung cancer oncologist at the centre of China's PD-1 and bispecific antibody trials, including ivonescimab in EGFR-mutant disease.","summary":"Wenfeng Fang is Professor of Medical Oncology at Sun Yat-sen University Cancer Center in Guangzhou. He is a lung cancer oncologist at the centre of China's PD-1 and bispecific antibody trials, having led or co-led studies of camrelizumab, of the Akeso PD-1 and VEGF bispecific ivonescimab in HARMONi-A, and of other immunotherapies in non-small-cell lung cancer and nasopharyngeal carcinoma. His publications include the HARMONi-A phase 3 trial of ivonescimab plus chemotherapy in EGFR-mutant lung cancer after progression on an EGFR tyrosine kinase inhibitor. His interests are lung cancer, immunotherapy, nasopharyngeal carcinoma and bispecific antibodies.","asOf":"2026-09-08","links":[{"label":"Sun Yat-sen University Cancer Center","url":"https://www.sysucc.org.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fang%20W%5BAuthor%5D%20Sun%20Yat-sen%20ivonescimab"}],"tags":[],"related":[],"cancers":["nsclc","head-and-neck"],"sections":[],"technologies":[],"targets":["pd1","vegf"],"drugs":["ivonescimab","camrelizumab"],"companies":["akeso"],"institutions":["sysucc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology, Sun Yat-sen University Cancer Center","institutionId":"sysucc","specialisms":["Lung cancer","Immunotherapy","Nasopharyngeal carcinoma","Bispecific antibodies"],"profiles":[{"label":"Sun Yat-sen University Cancer Center","url":"https://www.sysucc.org.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fang%20W%5BAuthor%5D%20Sun%20Yat-sen%20ivonescimab"}],"papers":[{"title":"Ivonescimab plus chemotherapy in NSCLC with EGFR variant after EGFR-TKI: the HARMONi-A phase 3 randomized clinical trial","journal":"JAMA","year":2024,"doi":"10.1001/jama.2024.10613"}]},"route":"/people/fang-wenfeng/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"},{"id":"vegf","kind":"target","name":"VEGF / VEGFR","route":"/targets/vegf/"}],"drug":[{"id":"camrelizumab","kind":"drug","name":"Camrelizumab","route":"/drugs/camrelizumab/"},{"id":"ivonescimab","kind":"drug","name":"Ivonescimab","route":"/drugs/ivonescimab/"}],"company":[{"id":"akeso","kind":"company","name":"Akeso","route":"/companies/akeso/"}],"institution":[{"id":"sysucc","kind":"institution","name":"Sun Yat-sen University Cancer Center","route":"/institutions/sysucc/"}],"trial":[{"id":"harmoni-a","kind":"trial","name":"HARMONi-A","route":"/trials/harmoni-a/"}]}}